The disease can also occur with other malignancies such as lymphoproliferative disorders, malignant thymoma, and rarely carcinoma of the breast, stomach, colon, prostate, and bladder [ 4 , 5 ].
MG may improve, worsen, or remain stable during pregnancy; however, a significant risk of deterioration in the puerperium was reported [ 1 , 4 ].
Severe respiratory insufficiency can be triggered by the physical stress of labor and delivery; similarly, patients with eclampsia during pregnancy have a higher risk of complications of both conditions, considering, for example, that magnesium sulfate cannot be used in MG patients [ 5 ].
It should also be noted that a newborn from a myasthenic pregnancy has a higher risk to develop TNMG see above. Currently, women with MG are advised to delay pregnancy until after the disease is stable [ 1 , 4 ] Table 2. Frequent symptoms: fatigue, weakness of the proximal muscles particularly in the legs , hyporeflexia, and dysautonomic manifestations.
Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3. Help us write another book on this subject and reach those readers. Login to your personal dashboard for more detailed statistics on your publications. Edited by Nima Rezaei. We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals.
Downloaded: Abstract Despite advances in applied sciences, myasthenia gravis MG remains a challenging disorder to diagnose and treat. Keywords myasthenia gravis transient or persistent weakness skeletal muscles thymoma. Table 1. Clinical manifestations of myasthenia gravis. Table 2. Myasthenia gravis subtypes and specific clinical situations—Summarized features. More Print chapter. How to cite and reference Link to this chapter Copy to clipboard.
Available from:. Over 21, IntechOpen readers like this topic Help us write another book on this subject and reach those readers Suggest a book topic Books open for submissions. More statistics for editors and authors Login to your personal dashboard for more detailed statistics on your publications.
Access personal reporting. More About Us. Articulation Face Chewing Swallowing Neck. Prominent weakness in the cranial, bulbar, and respiratory muscles Myasthenic symptoms more severe than in non-MuSK-MG patients.
May occur in infants born to mothers with autoimmune MG The myasthenic symptoms resolve within the first month of life with treatment. The disease onset occurs before age 18 High rate of spontaneous remission. A test that measures the electrical activity of a muscle. An EMG can detect abnormal electrical muscle activity due to diseases and neuromuscular conditions.
Specific treatment for myasthenia gravis will be determined by your healthcare provider based on:. There is no cure for myasthenia gravis, but the symptoms can often be controlled. Myasthenia gravis is a lifelong medical condition. Early detection is the key to managing the condition. The goal of treatment is to increase muscle function and prevent swallowing and breathing problems. Most people with this condition can improve their muscle strength and lead normal or near normal lives.
In more severe cases, help may be needed for breathing and eating. This is surgical removal of the thymus gland. The role of the thymus gland in myasthenia gravis is not fully understood, and the thymectomy may or may not improve symptoms. A procedure that removes abnormal antibodies from the blood and replaces the blood with normal antibodies from donated blood.
It is given intravenously IV. The most serious complications of myasthenia gravis is a myasthenia crisis. This is a condition of extreme muscle weakness, particularly of the diaphragm and chest muscles that support breathing. Breathing may become shallow or ineffective. The airway may become blocked because of weakened throat muscles and build up of secretions. Objective To assess the effect of oral corticosteroid therapy on the frequency of development of generalized myasthenia gravis within 2 years, the incidence of thymoma, and the amount of edrophonium needed for a positive test result in patients with ocular myasthenia gravis.
Methods We reviewed an ocular myasthenia gravis database of patients. Patients underwent measurement of acetylcholine receptor AChR antibody levels and chest computed tomography.
Most continued to receive daily or alternate-day doses of 2. Patients not given prednisone untreated group received pyridostigmine bromide or no medication. After the diagnosis, we documented the signs and symptoms of ocular and generalized myasthenia gravis and performed 2-year follow-up in 94 patients. Results The mean dose of edrophonium chloride to give a positive response was 3. Thymoma occurred in 1 patient 0.
Generalized myasthenia gravis developed within 2 years in 4 of 58 treated and 13 of 36 untreated patients. The odds ratio OR for development of generalized disease in the treated group was 0.
The AChR antibody level was not predictive of development of generalized myasthenia gravis at 2 years, but the risk was greater in patients with abnormal AChR antibody levels OR, 6.
Logistic regression that included age, abnormal AChR antibody level, and prednisone therapy yielded significance only for abnormal AChR antibody level OR, 7.
Thymoma, although uncommon, occurs in ocular myasthenia gravis. Only small amounts of edrophonium are needed to diagnose ocular myasthenia gravis. Ocular myasthenia gravis is bothersome in that it causes visual disability and dysfunction of daily living activities, but generalized myasthenia gravis is a potentially life-threatening illness.
If a low-cost, reasonably safe therapy could reduce the frequency of deterioration of ocular myasthenia gravis to the generalized form of the disease, the obvious benefits would include prevention of debilitating disease, long-term immunosuppressive therapies, and hospitalizations. If larger dosages are used for a short time, few major adverse effects should result, even if lower doses are continued for many months.
We extracted the data to fill in an ocular myasthenia gravis database created in All new and old patients with ocular myasthenia gravis who came to the clinics from forward had their medical chart data maintained in a systematic matter, and all were informed of the intention to keep their data in an organized confidential database to try to answer the questions of this study.
Inclusion criteria consisted of being 2 years or older at the first neuro-ophthalmologic examination and having clinically evident ocular myasthenia gravis and no subjective symptoms or clinical findings suggestive of generalized myasthenia gravis any muscle weakness below the neck or in the facial muscles except the orbicularis oculi.
We used the following criteria for diagnosis of ocular myasthenia gravis:. Ptosis in one or both upper lids not due to local eyelid disease, preferably that could fatigue or recover with rest. Extraocular muscle weakness in one or both eyes, not in a strict third nerve muscle innervation pattern; if the weakness was in the lateral rectus only, clear-cut fatigability, recovery, or a positive edrophonium chloride test results.
Weakness that could be present in one or both orbicularis oculi but no other weakness of the muscles of the head and neck. Fatigue of the affected muscle with clear-cut worsening of the ptosis after upward gaze for 30 to 60 seconds or worsening of the monocular duction after seconds of gaze in the direction of action 1 , 11 ; recovery of the upper-eyelid ptosis to almost normal after 30 seconds to 10 minutes of eyelid closure, and recovery of the monocular duction after to seconds of gaze in the direction of the antagonist muscle 11 , 12 ; or a positive edrophonium chloride test result.
Patients with ocular myasthenia gravis beginning before age 2 years were excluded. Patients with signs of restrictive myopathy of abduction or supraduction due to dysthyroid ophthalmopathy were excluded. Patients with dysthyroid ophthalmopathy who developed exotropia and a positive edrophonium test were incuded. The edrophonium test was performed as previously described.
The infusion was aborted when a clear positive response occurred. The number of milligrams required to reach the end point was documented. All patients underwent contrast-enhanced computed tomography CT of the chest to look for the presence of a thymoma. The serum was tested for fasting blood glucose and AChR-binding antibody levels performed in several different commercial laboratories.
Patients underwent blood studies for thyroid dysfunction unless they were already known to have a history of hypothyroidism or hyperthyroidism. Patients were not randomized for therapy. Because previous work suggested that corticosteroids alleviate diplopia in the primary gaze, 4 except in patients who refused or had contraindications, patients with diplopia in primary or downward gaze and extraocular muscle dysfunction or ptosis that blocked vision and was unresponsive to pyridostigmine bromide were treated with prednisone treated group.
Patients with these exceptions, including active gastrointestinal tract ulcer or a history of tuberculosis, diabetes mellitus that was difficult to control, severe hypertension, and congestive heart failure, and patients who refused treatment, constituted the untreated group. The duration of symptoms before starting treatment was not uniform.
The dosage was further reduced by 2. Most patients in the prednisone treatment group continued to receive a daily or alternate daily dose of 2.
Patients not treated with prednisone received pyridostigmine as necessary and tolerated to relieve ptosis. There are several therapies available to help reduce and improve muscle weakness.
With treatment, most individuals with myasthenia can significantly improve their muscle weakness and lead normal or nearly normal lives.
Some cases of myasthenia gravis may go into remission—either temporarily or permanently— and muscle weakness may disappear completely so that medications can be discontinued. Stable, long-lasting complete remissions are the goal of thymectomy and may occur in about 50 percent of individuals who undergo this procedure. The mission of the National Institute of Neurological Disorders and Stroke NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
Although there is no cure for myasthenia gravis, management of the disorder has improved over the past 30 years. There is a greater understanding about the causes, structure and function of the neuromuscular junction, the fundamental aspects of the thymus gland and of autoimmunity. Technological advances have led to more timely and accurate diagnosis of myasthenia gravis and new and enhanced therapies have improved treatment options.
Researchers are working to develop better medications, identify new ways to diagnose and treat individuals, and improve treatment options. Some people with myasthenia gravis do not respond favorably to available treatment options, which usually include long-term suppression of the immune system. New drugs are being tested, either alone or in combination with existing drug therapies, to see if they are more effective in targeting the causes of the disease.
In addition to developing new medications, researchers are trying to find better ways to diagnose and treat this disorder. For example, NINDS-funded researchers are exploring the assembly and function of connections between nerves and muscle fibers to understand the fundamental processes in neuromuscular development.
This research could reveal new therapies for neuromuscular diseases like myasthenia gravis. New treatment options Findings from a recent NINDS-supported study yielded conclusive evidence about the benefits of surgery for individuals without thymoma, a subject that had been debated for decades.
Researchers hope that this trial will become a model for rigorously testing other treatment options, and that other studies will continue to examine different therapies to see if they are superior to standard care options.
Assistive technologies, such as magnetic devices, may also help people with myasthenia gravis to control some symptoms of the disorder. Box Bethesda, MD www.
0コメント